This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 2NJ
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en 2NJ a partir de nuestros controles de riesgos.
Competidores de Covetrus, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.52 |
| 52 Week High | US$21.60 |
| 52 Week Low | US$12.89 |
| Beta | 1.51 |
| 1 Month Change | 3.96% |
| 3 Month Change | 6.06% |
| 1 Year Change | 25.85% |
| 3 Year Change | 119.59% |
| 5 Year Change | n/a |
| Change since IPO | -34.77% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 2NJ | DE Healthcare | Mercado DE | |
|---|---|---|---|
| 7D | 1.3% | -4.8% | -1.7% |
| 1Y | 25.8% | -0.06% | 6.2% |
Rentabilidad vs. Industria: 2NJ exceeded the German Healthcare industry which returned -47.3% over the past year.
Rentabilidad vs. Mercado: 2NJ exceeded the German Market which returned -28.4% over the past year.
Volatilidad de los precios
| 2NJ volatility | |
|---|---|
| 2NJ Average Weekly Movement | 2.4% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: 2NJ has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: 2NJ's weekly volatility (2%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2018 | 4,873 | Ben Wolin | www.covetrus.com |
Resumen de fundamentos de Covetrus, Inc.
| Estadísticas fundamentales de 2NJ | |
|---|---|
| Capitalización bursátil | €3.01b |
| Beneficios(TTM) | -€13.31m |
| Ingresos (TTM) | €4.76b |
0.6x
Ratio precio-ventas (PS)-226.3x
Ratio precio-beneficio (PE)¿Está 2NJ sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 2NJ | |
|---|---|
| Ingresos | US$4.65b |
| Coste de los ingresos | US$3.77b |
| Beneficio bruto | US$882.00m |
| Otros gastos | US$895.00m |
| Beneficios | -US$13.00m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.093 |
| Margen bruto | 18.97% |
| Margen de beneficio neto | -0.28% |
| Ratio deuda/patrimonio | 68.7% |
¿Cómo se ha desempeñado 2NJ a largo plazo?
Ver rendimiento histórico y comparativa